Suchergebnisse - "van Engen, Anke"

PubPharm (10)

1

enthalten in: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | 2022

von Patel, D. | van Engen, A. | Kim, J.

2

Use of External Comparators for Health Technology Assessment Submissions Based on Single-Arm Trials

enthalten in: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | 2021

von Patel, D. | Grimson, F. | Mihaylova, E. | +4

CommentIn: Value Health. 2022 Jul;25(7):1253-1256. - PMID 35256243

3

"De-escalation" strategy using micafungin for the treatment of systemic Candida infections : budget impact in France and Germany

enthalten in: ClinicoEconomics and outcomes research : CEOR | 2017

von van Engen, A. | Casamayor, M. | Kim, S. | +2

4

Cost-effectiveness of a fixed-dose combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with lower urinary tract symptoms associated with benign prostatic hyperplasia

enthalten in: BMC urology | 2015

von Nazir, J. | Heemstra, L. | van Engen, A. | +2

5

Cost-effectiveness of a fixed-dose combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with lower urinary tract symptoms associated with benign prostatic hyperplasia

enthalten in: BMC urology | 2015

von Nazir, J. | Heemstra, L. | van Engen, A. | +2

6

Cost-effectiveness of a fixed-dose combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with lower urinary tract symptoms associated with benign prostatic hyperplasia

enthalten in: BMC urology | 2015

von Nazir, J. | Heemstra, L. | van Engen, A. | +2

7

Economic Evaluation of Fidaxomicin for the Treatment of Clostridium Difficile Infection (C. difficile-associated diarrhoea) in Ireland

enthalten in: Journal of health economics and outcomes research | 2015

von van Engen, A. | Casamayor, M. | Loftus, F. | +4

8

Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection

enthalten in: The Journal of antimicrobial chemotherapy | 2014

von Nathwani, D. | Cornely, O. | Van Engen, A. | +3

9

De-escalation from micafungin is a cost-effective alternative to traditional escalation from fluconazole in the treatment of patients with systemic Candida infections

enthalten in: Journal of medical economics | 2013

von Masterton, R. | Casamayor, M. | Musingarimi, P. | +4

10

Pharmacoeconomic model of topical treatment options of mild to moderate psoriasis vulgaris in Germany

enthalten in: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG | 2009

von Augustin, M. | Radtke, M. | van Engen, A. | +3

1
[1]